Vaccine plus chemotherapy after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial combines a new vaccine (XH001) with chemotherapy after surgery for pancreatic cancer. The vaccine aims to train your immune system to fight any remaining cancer cells, potentially lowering the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to remove pancreatic cancer, and the surgeon got all visible cancer (or left only tiny amounts, called R0 or R1).
- You have not had chemotherapy or radiation before your surgery.
- You are generally in good health (able to do daily activities, with an ECOG score of 0 or 1).
- You do not have cancer that has spread to other parts of the body or come back after surgery.
- You do not have an autoimmune disease or a history of severe heart problems, stroke, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
This trial tests whether adding the drug ivonescimab to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. The treatment is given for a short time to shrink the tumor and make surgery more likely to succeed.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.